Derisking Development by a Cocrystallization Screen of a Novel Selective Inhaled JAK-STAT inhibitor [component]

unpublished
18 19 20 21 22 Antonio Llinas Antonio.Llinas@astrazeneca.com 23 Rafel Prohens rafel@ccit.ub.edu 24 25 26 27 28 ABSTRACT: 29 30 The discovery and detailed characterization of several new solid forms of a novel selective inhaled JAK-31 STAT inhibitor are described. Using a holistic cocrystallization screen approach to explore its 32 formulation landscape, we decrease the risk of future potential development failures due to a nonoptimal 33 pharmacokinetic lung profile or undesired lung effects in
more » ... ed lung effects in humans. 34 35 .. 36
doi:10.1021/acs.cgd.8b01492.s001 fatcat:u4dxalrhi5d63hbo7kuyrabgf4